Cart
This product is not clubbable with other items in cart. Please remove this or other items to proceed further.
Deleting

No Items In Cart
This product is not clubbable with other items in cart. Please remove this or other items to proceed further.
No Items In Cart
改善药物纯度的投资
West FluroTec活塞可以:
在模制过程中,FluroTec膜被施加于胶塞表面,这种膜可适应如干粉和冻干制剂所需的复杂形状的密封系统。 西氏FluroTec的覆膜冻干制剂胶塞具有单叉设计,已经证明可有效减少双叉胶塞在工艺流程中可能出现的扭成对和交锁
*非FluroTec尺寸可用于不同的配置
西氏已经完成研究,确保组件能够轻松地整合到客户的药品灌装-包装生产工艺中。从概念到市场,西氏都与客户并肩合作,使组件能满足多种包装需求。
小容量:
散装袋
传送接口袋:
There is no doubt biologics and biosimilars will remain one of the hot topics in 2021. This is due to the pandemic period of SARS-CoV-2 and the innovative treatments and vaccines that are under development at accelerated speed. Several questions can arise regarding selection of the proper primary package system for a biologic/biosimilar.
Nancy Liu
Sr. Specialist, TCS. CN
An enormous growth trend is being observed in the market for biologic drugs; they are being employed ever more frequently as treatments for chronic issues such as cancer and autoimmune diseases. This growth is reflected by the number of companies involved (established and emerging), and in the capital investment for manufacturing facilities for both biologics and biosimilars. Companies must apply a holistic approach to bringing a biologic drug to market.
Nancy Liu
Sr. Specialist, TCS, China
In recent years, an increasing variety of biologic drugs have been developed including vaccines, recombinant proteins, gene and cell therapies. In China, this increased demand will be reflected in a significant growth in the size of the bio-pharmaceutical industry. As a result, the Chinese government is increasing its investment.
Lynn Yao
Manager, Scientific Affairs, China
There is no doubt biologics and biosimilars will remain one of the hot topics in 2021. This is due to the pandemic period of SARS-CoV-2 and the innovative treatments and vaccines that are under development at accelerated speed. Several questions can arise regarding selection of the proper primary package system for a biologic/biosimilar.
Nancy Liu
Sr. Specialist, TCS. CN
An enormous growth trend is being observed in the market for biologic drugs; they are being employed ever more frequently as treatments for chronic issues such as cancer and autoimmune diseases. This growth is reflected by the number of companies involved (established and emerging), and in the capital investment for manufacturing facilities for both biologics and biosimilars. Companies must apply a holistic approach to bringing a biologic drug to market.
Nancy Liu
Sr. Specialist, TCS, China
In recent years, an increasing variety of biologic drugs have been developed including vaccines, recombinant proteins, gene and cell therapies. In China, this increased demand will be reflected in a significant growth in the size of the bio-pharmaceutical industry. As a result, the Chinese government is increasing its investment.
Lynn Yao
Manager, Scientific Affairs, China